We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PXS Provexis Plc

0.00 (0.0%)
01 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Provexis Plc LSE:PXS London Ordinary Share GB00B0923P27 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.50 10,810 00:00:00
Bid Price Offer Price High Price Low Price Open Price
0.45 0.55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Food Preparations, Nec 390k -385k -0.0002 -25.00 11.09M
Last Trade Time Trade Type Trade Size Trade Price Currency
10:39:40 O 10,810 0.455 GBX

Provexis (PXS) Latest News

Provexis (PXS) Discussions and Chat

Provexis (PXS) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Provexis (PXS) Top Chat Posts

Top Posts
Posted at 02/12/2023 08:20 by Provexis Daily Update
Provexis Plc is listed in the Food Preparations, Nec sector of the London Stock Exchange with ticker PXS. The last closing price for Provexis was 0.50p.
Provexis currently has 2,217,821,523 shares in issue. The market capitalisation of Provexis is £11,089,108.
Provexis has a price to earnings ratio (PE ratio) of -25.00.
This morning PXS shares opened at -
Posted at 04/11/2023 13:38 by redprince
winner - a word of caution on our main share holder - a lot of people took a false sense of comfort when the lawyer bought a significant holding in the company years ago.Stuart Lucas is in this for what he can make same as the rest of us - he could try and take this private and it may not be at a price that some are happy with.

So that underlines why i would not entertain any talk of a t/o until we can see the income from By-Health after a year of sales.

Hopefully SL is in this for the long term and that is very much in our better interests as if so he would help us to steer clear of a cheeky early doors offer.

Posted at 31/10/2023 18:51 by redprince
Informer - thank you for taking the time to both attend and feed back to the rest of us who did not attend.I have been to x 3 pxs agm's and the SIS meeting and its quite expensive for me as i live far away so i do appreciate your attendance and feedback.

Much of what you reorted makes sense apart from the absence of doubling up in our accounts although that may show later?

My biggest concern is the prospect of a 75% majority agreeing to a take out once By-Health get going.For all i know Stuart Lucas could get behind that and after 14+ years
and a substantial stake here i dont want to get taken out on the cheap!!

Anyway i am hoping to have some funds available in the new year and if everything works out i am willing to buy more so that i can live with whatever happens.Still think there is going to be plenty of time before By-Health get the SAMR completed.

Thanks again.
Posted at 30/10/2023 20:48 by winner31
Thanks informer . DSM customers stocking up before the transfer makes sense , looking forward their stocks won’t last that long , so they’ll soon be reordering from pxs . The more I read about DSM the more it seems they were throwing their toys out of the pram when pxs broke away , makes you wonder if their plan was to buy- out pxs on the cheap and IF has thrown a spanner in their works . Hopefully we can grow sales from now on with new customers , and when Byhealth launch their products a bid would be very welcome . Also good news that dilution probably not going to happen !
Posted at 30/10/2023 20:01 by informer
Re: Provexis AGM 2023

Although the ideal opportunity to hold IF to account I am pretty sure nobody here managed to attend. I do believe that most of you live some way from London and especially in the light of the largely negative sentiment and rightly so - especially by those who have held the longest - may have found the trip difficult to justify.

It seemed that shareholders who did attend entered the room sharing exactly the same negativity. However with the exception of the De-Rampers for RedPrince, Gixer, Winner, Bareknee etc there were one or two interesting points which may offer just a bit of encouragement.

Whilst IF acknowledged that figures to March 31st were uninspiring and in particular DSM Sales it was stated that most customers had been encouraged prior to December 31st to double up on order quantities resulting in PXS inheriting an overstocked customer base. He confirmed that he was committed to increasing Shareholder value and that he was currently in discussion with a number of third parties to progress new sales and distribution opportunities for Fruitflow and that independent sales teams have been incentivised in this respect.

He confirmed that despite numerous requests DSM had been unable to provide him with any sales forecasts going forward.

IF re-iterated that in the 6 months following year end Sales of Fruitflow II SD ingredient in excess of £280k and confirmed Sales Orders in excess of £155k were currently being processed and that the company is dealing with numerous enquiries from both new and existing customers. There appeared a genuine positivity in this respect and hope we can look forward to positive Interims come December.

It was explained that IF had insisted on payment up front from all DSM customers which had been accepted in every case thus adding no additional pressure on Cash Flow.

He also stated that as DSM stocks of Fruitflow were of no use to anyone else he felt he was in the driving seat and negotiations were ongoing bearing in mind best before dates etc etc.

IF intimated that future business would be self funding and that he would only consider share dilution as a last resort.

R&D costs were questioned - we have an amazing product - the science is good why are we not spending on Sales as opposed to R&D - it was explained that most of the R&D costs relate to maintaining Patents and that the cost of each goes up annually.

It was felt that the value of the company is equal to the value of its Patents.

Clearly all are pinning hopes on By Health and encouraged that no sooner had the new SAMR Implementation Rules been published By Health the very next day made its application for Fruitflow approval as a new permitted health function to maintain normal platelet aggregation.

Apparently Felix is working in China on a British Passport obtained with the help from Provexis - no idea about this one.

Finally after the meeting had finished there seemed a genuine air of positivity with the talk of takeover in the new year as the main source of conversation.

Also Stuart Lucas is not a stupid man why would he feel the need to add to his holding - perhaps he knows something you don't ?

E&OE This is not word for word and apologies if I have missed out or misinterpreted anything - don't shoot the messenger - take it for what it is.
Posted at 10/10/2023 20:01 by winner31
From bitter experience I am always wary of Aim Bod , have lost a huge amount on one Aim share in the past so I scrutinise everything directors say and when they don’t deliver I am even more suspicious . I think the bod have pinned everything on Byhealth getting Bluehat and as BB said it would mean little work on marketing and promotion but I think this is a lazy attitude for shareholders ,I think we deserve better . I hope the bod have something else to tell us soon !even a fund raise would be welcome at the moment.
Posted at 10/10/2023 06:28 by gix er
Can't disagree with your figures BB but my concern is the obvious fall in revenue from the AA over the last few years. I have no idea if this is down to fewer sales or an increase in the price for FF (or both) as an ingredient but it doesn't look great.

We were told that "The customers which are set to be transferred to Provexis represent a significant majority of DSM's total sales of Fruitflow". So where have they gone and what is IF doing to attract (old and) new customers?

There is no obvious link, that i can find, that would direct new customers for FF to provexis. Relying on DSM sending new or existing customers to us is not a great idea.
Posted at 01/9/2023 20:18 by redprince
I am going in the middle wrt timescale here.It would probably take a >= 1 year if the pre submission work had not been as thorough but given the work that By-Health have done and that they have been working steadfastly toward this end i believe we are looking at 6 months to under a year.

Once again this week we saw folks grasping at straws after the somewhat ambiguous rns trying to interpret it as tens of millions USD.We knew from before that originally the sum was in the ballpark of £1 million so with the extra trials that has grown to £2 million not tens of million gbp.

What we dont know is the likelihood and quantum of extra funding that may be needed.

Anyway it is good to know that the submission is underway at long last.

Clearly By-Health are very keen on FF but again we have no idea what our margin is likely to be.

My gut tells me it is likely to be several years before we can ascertain the scope of the deal with any real clarity - time for sales to build and profit to accrue to pxs.

Not withstanding a price spike on news of product launch i suspect a lot of pi's will look to bail "early" and the price is likely to be volatile until it all settles down and revenues become more predictable.

Hard to believe it has taken this long!
Posted at 11/8/2023 14:39 by nestoframpers
I reckon if anything good should happen to PXS ( yawn ) they will spike the share price to get LTHs to get out once they are not under water ( we will be so grateful) , then it will slowly fall and then, out of the blue .......
Posted at 17/5/2020 11:21 by winner31
Rich i have always thought that DSM have their own agenda when it comes to ff , of course it would be in their interest to not allow the pxs share price to get ahead of itself with regard to market cap ,we all know what happened 10 years or so ago , does anyone else think it’s strange that some years DSM throw £20 or 30k for marketing and so boosting the revenue of pxs and the the next year nothing , so flattening out any spikes in revenue and so the share price , all looks to me like they will make a bid at some stage but only what they want to pay and no more ,may be 3p which in my opinion way under values the potential of the technology .
Posted at 19/10/2019 14:49 by winner31
Notable News Buzz: Provexis Plc, (LON: PXS)

October 18, 2019 No Comments LON: PXSProvexis Plc
On Thursday the Provexis Plc, LON: PXS), the Trending-Graph. Every buying and selling session display one-of-a-kind measures and patterns about PXS stock.Now we observed the Many factors that seen on close of the Previous session. Toward the day’s end, it’s only a stock’s show that issues.

Summary Of The Provexis Plc In Stock Exchange LON:

The PXS share price closed at 0.38 with the change of 0.03 during the period of last trading session. Trading volume can help an investor to identify the momentum in a stock and confirm a trend. If trading volume raised, prices generally move in a similar direction. That is, if security is proceeding higher in an uptrend, the volume of the protection should also increase and vice versa. The Company’s current volume remained at 3424534.00. It will be even better to share yesterday’s volume of the Company, i.e., 1237316.00.

Market Capitalization of Provexis Plc :

Market Capitalization is the accurate measure of a company’s value. There’s a common misconception that a company’s each-share stock price holds as much importance as its market capitalization when it comes to picking stocks to buy. This fallacy occurs especially often in the case of new investors. The market capitalization of the Company recorded at PXS.

Buy/Sell/Hold Analysis of PXS:

Buy Signals: An event or condition that alerts a person to place a purchase order for an investment. Buy signals can be either observed by analyzing chart patterns or calculated by trading systems.

Hold Signals: An analyst’s recommendation to neither purchase nor sell a security. A company or organization with a hold recommendation mostly is required to perform with the market or a similar pace as comparable companies.
Provexis share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |